An advisory committee of the Centers for Disease Control and Prevention voted to federal expansion “suspend” Johnson & Johnson’s COVID-19 vaccination cessation due to concerns about serious blood clots. Weights were reported in six people who received J&J injections.
Shares of Johnson & Johnson
a 0.4% drop in extended trading Wednesday after the close of normal trade slightly up.
The heralded single-dose J&J vaccine rollout sparked frustration this week as federal health officials said Six serious cases of blood clotting have been reported among the nearly 7 million individuals who have received J&J in the US Members of the Biden administration has sought to reassure the public Vaccine safety is a priority and the full coverage of the national immunization program remains.
The severity of the cases – one woman dies and all six hospitalized in intensive care units – has led the CDC and the Food and Drug Administration to recommend a “pause” immunization with this vaccine on Tuesday.
Blood clots occur due to cerebral sinus thrombosis combined with thrombocytopenia, a condition that causes low platelet counts in the blood.
“Although a causal relationship has not yet been fully established between these very rare events and our vaccines, we have found that these events may represent a potentially significant risk. on Janssen vaccines, ”said Dr. Aran Maree, medical director of J & J’s drug business, during the meeting.
CDC Advisory Committee on Immunization Practice, convened one emergency meeting To discuss the potential risks of the vaccine on Wednesday voted to extend the “pause” time and will reconnect on an unknown date. It plans to provide the date of its next meeting on Friday.
Much of the discussion at the end of the meeting focused on whether committee members need more clinical information before making a formal recommendation or waiting to make a choice that further harms people. Americans are at risk for COVID-19 infection.
“We are in a situation where not making a decision is the equivalent of making a decision and extending the pause will always lead to the fact that the most vulnerable people in the United States are The top candidate for the Johnson and Johnson vaccine will remain vulnerable, ”said Dr. Nirav Shah, the CDC director of Maine and an advisory committee member, during the meeting.
The J&J injection has been seen as an easier and fairer tool in the nation’s mass immunization program as it only requires one shot and can be given in people’s homes or residencies. moving.
Additional details were shared on six cases during the ACIP meeting. All six cases were in white women between the ages of 18 and 48. Three were considered obese, and none were pregnant or postpartum. The average time it takes for symptoms to appear is eight days, and five out of six people report a headache as an initial symptom.
A case of CVST has been reported in a clinical trial, in a 25-year-old white man, even though he did not have low platelet counts.
There are no reports of thrombocytopenic CVSTs among people who took Pfizer Inc.
or Moderna Inc.
Preventive vaccine covid-19. Both injections are adenovirus vector-based vaccines, although the AstraZeneca vaccine is licensed in Europe and the UK but not in the US.
Several countries have since made age-based recommendations for the AstraZeneca vaccine. In the UK it is recommended for adults over 30 years old; Australia recommends it for people over 50 years old; and Europe now says it should be used for people between the ages of 55 and 70.
Shares in J&J have risen 1.6% since the start of the year, while the S&P 500 is broader
• Read presentation of the presenter from the ACIP meeting
• See emergency meeting
• Read Health warning of the CDC